Korean J Obstet Gynecol.  2004 Feb;47(2):367-371.

Ovarian Malignant Mixed Mullerian Tumor Managed with Neoadjuvant Chemotherapy and Cytoreductive Surgery

• Kang MS
• Kim SM
• Choi HS
• Lee YG

Abstract

Malignant mixed Mullerian tumor(MMMT) of the ovary is very uncommon neoplasm consisting of both a sarcomatous and carcinomatous component. These tumors usually present in an advanced stage and are characterized by rapid growth and poor survival and appropriate treatment remained controversial. The patients with advanced stage ovarian cancer could only benefit from an optimal surgical debulking. However, the optimal cytoreductive surgery may often be difficult to achieve due to the initial extent of the disease. Thus primary surgery for this subset of patients may be questionable. So, we tried neoadjuvant Taxol and/or cis-platinum combined chemotherapy as primary treatment. At the end of neoadjuvant chemotherapy, the patient showed markedly decrease of serum CA 125 level(from 210 U/ml to 59 U/ml) and optimal cytoreductive surgery was performed. After surgery, adjuvant chemotherapy was administered and the serum CA 125 level decreased to the normal range. This case shows our experience of neoadjuvant chemotherapy followed by cytoreductive surgery and adjuvant chemotherapy in patient with primarily unresectable ovarian malignant mixed Mullerian tumor(MMMT).

Keyword

MMMT(Malignant mixed Mullerian tumor); Ovary

MeSH Terms

Chemotherapy, Adjuvant
Cisplatin
Drug Therapy*
Female
Humans
Ovarian Neoplasms
Ovary
Paclitaxel
Reference Values
Cisplatin
Paclitaxel